Mitochondria and neurodegenerative diseases: the promising role of nanotechnology in targeted drug delivery

References

• Hroudová J, Singh N, Fišar Z. Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer’s disease. Biomed Res Int. 2014;2014:175062.
   PubMed Web of Science ®Google Scholar
• Konat GW, Wiggins RC. Effect of reactive oxygen species on myelin membrane proteins. J Neurochem. 1985;45:1113–1118.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang F, Li L, et al. MFN2 couples glutamate excitotoxicity and mitochondrial dysfunction in motor neurons. J Biol Chem. 2015;290:168–182.
   PubMed Web of Science ®Google Scholar
• Souto EB, Severino P, Basso R, et al. Encapsulation of antioxidants in gastrointestinal-resistant nanoparticulate carriers. Methods Mol Biol. 2013;1028:37–46.
   PubMedGoogle Scholar
• Bondì ML, Di Gesù R, Craparo EF. Lipid nanoparticles for drug targeting to the brain. Methods Enzymol. 2012;508:229–251.
   PubMed Web of Science ®Google Scholar
• Arun S, Liu L, Donmez G. Mitochondrial biology and neurological diseases. Curr Neuropharmacol. 2016;14:143–154.
   PubMed Web of Science ®Google Scholar
• Brieger K, Schiavone S, Miller FJ, et al. Reactive oxygen species: from health to disease. Swiss Med Wkly. 2012;142:w13659.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Harashima H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev. 2008;60:1439–1462.
   PubMed Web of Science ®Google Scholar
• Morais VA, De Strooper B. Mitochondria dysfunction and neurodegenerative disorders: cause or consequence. J Alzheimers Dis. 2010;2:255–263.
   Web of Science ®Google Scholar
• Federico A, Cardaioli E, Da Pozzo P, et al. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci. 2012;322:254–262.
   PubMed Web of Science ®Google Scholar
• Kumar A, Singh A. A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions. Front Pharmacol. 2015;6:206.
   PubMed Web of Science ®Google Scholar
• Pathak RK, Kolishetti N, Dhar S. Targeted nanoparticles in mitochondrial medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7:315–329.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Akita H, Kogure K, et al. Mitochondrial drug delivery and mitochondrial disease therapy-an approach to liposome-based delivery targeted to mitochondria. Mitochondrion. 2007;7:63–71.
   PubMed Web of Science ®Google Scholar
• Sheu SS, Nauduri D, Anders MW. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta. 2006;1762:256–265.
   PubMed Web of Science ®Google Scholar
• Quinzii CM, Hirano M, Di Mauro S. CoQ10 deficiency diseases in adults. Mitochondrion. 2007;7:122–126.
   Web of Science ®Google Scholar
• McManus MJ, Murphy MP, Franklin JL. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. J Neurosci. 2011;31:15703–15715.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Chandran K, Kalivendi SV, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson’s disease model. Free Radic Biol Med. 2010;49:1674–1684.
   PubMed Web of Science ®Google Scholar
• Jauslin ML, Meier T, Smith RA, et al. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 2003;17:1972–1974.
   PubMed Web of Science ®Google Scholar
• Gruber J, Fong S, Chen CB, et al. Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing. Biotechnol Adv. 2013;31:563–592.
   PubMed Web of Science ®Google Scholar
• Filipovska A, Kelso GF, Brown SE, et al. Synthesis and characterization of a triphenylphosphonium-conjugated peroxidase mimetic. Insights into the interaction of ebselen with mitochondria. J Biol Chem. 2005;280:24113–24126.
   PubMed Web of Science ®Google Scholar
• Kelso GF, Maroz A, Cochemé HM, et al. A mitochondria-targeted macrocyclic Mn(II) superoxide dismutase mimetic. Chem Biol. 2012;19:1237–1246.
   PubMed Web of Science ®Google Scholar
• Jin H, Kanthasamy A, Ghosh A, et al. Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: preclinical and clinical outcomes. Biochim Biophys Acta. 2014;1842:1282–1294.
   PubMed Web of Science ®Google Scholar
• Marrache S, Dhar S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci USA. 2012;109:16288–16293.
   PubMed Web of Science ®Google Scholar
• Tiwari SK, Agarwal S, Seth B, et al. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/β-catenin pathway. ACS Nano. 2014;8:76–103.
   PubMed Web of Science ®Google Scholar
• Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629–656.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Nakamura K, Abe J, et al. Mitochondrial delivery of coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver. J Control Release. 2015;213:86–95.
   PubMed Web of Science ®Google Scholar
• Zhang E, Zhang C, Su Y, et al. Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy. Drug Discov Today. 2011;16:140–146.
   PubMed Web of Science ®Google Scholar
• Picone P, Bondi ML, Montana G, et al. Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: improved delivery by solid lipid nanoparticles. Free Radic Res. 2009;43:1133–1145.
   PubMed Web of Science ®Google Scholar
• Sandhir R, Yadav A, Mehrotra A, et al. Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington’s disease. Neuromolecular Med. 2014;16:106–118.
   PubMed Web of Science ®Google Scholar
• Surekha R, Sumathi T. A novel therapeutic application of solid lipid nanoparticles encapsulated thymoquinone (TQ-SLNs) on 3-nitroproponic acid induced Huntington’s disease-like symptoms in wistarrats. Chem Biol Interact. 2016;S0009–2797:30190–30199.
   Google Scholar
• Vedagiri A, Thangarajan S, Mitigating effect of chrysin loaded solid lipid nanoparticles against Amyloid β(25-35) induced oxidative stress in rat hippocampal region: an efficient ormulation approach for Alzheimer’s disease. Neuropeptides. 2016; online doi:10.1016/j.npep.2016.03.002
   PubMed Web of Science ®Google Scholar
• Tanaka M, Borgeld HJ, Zhang J, et al. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. Biomed Sci. 2002;9:534–541.
   Google Scholar
• Tranebjaerg L, Schwartz C, Eriksen H, et al. A new X linked recessive deafness syndrome with blindness, dystonia, fractures, and mental deficiency is linked to Xq22. J Med Genet. 1995;32:257–263.
   PubMed Web of Science ®Google Scholar
• Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecule and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 2005;57:637–651.
   PubMed Web of Science ®Google Scholar
• Popiel HA, Nagai Y, Fujikake N, et al. Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo. Mol Ther. 2007;15:303–309.
   PubMed Web of Science ®Google Scholar
• Popiel HA, Nagai Y, Fujikake N, et al. Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice. Neurosci Lett. 2009;449:87–92.
   PubMed Web of Science ®Google Scholar
• Kovacic P, Somanathan R. Biomechanisms of nanoparticles (toxicants, antioxidants and therapeutics): electron transfer and reactive oxygen species. J Nanosci Nanotechnol. 2010 Dec;10:7919–7930.
   PubMed Web of Science ®Google Scholar
• Young AJ, Johnson S, Steffens DC, et al. Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr. 2007;12:62–68.
   PubMed Web of Science ®Google Scholar
• Shults CW, Beal MF, Fontaine D, et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology. 1998;50:793–795.
   PubMed Web of Science ®Google Scholar
• Ferrante KL, Shefner J, Zhang H, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. 2005;65:1834–1836.
   PubMed Web of Science ®Google Scholar
• Weyer G, Babej-Dölle RM, Hadler D, et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology. 1997;36:73–82.
   PubMed Web of Science ®Google Scholar
• Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999;157:142–149.
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999;5:347–350.
   PubMed Web of Science ®Google Scholar
• Bender A, Samtleben W, Elstner M, et al. Long-term creatine supplementation is safe in aged patients with Parkinson disease. Nutr Res. 2008;28:172–178.
   PubMed Web of Science ®Google Scholar
• Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2ʹdG. Neurology. 2006;66:250–252.
   PubMed Web of Science ®Google Scholar
• Abdel-Kader R, Hauptmann S, Keil U, et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res. 2007;56:493–502.
   PubMed Web of Science ®Google Scholar
• Trujillo J, Granados-Castro LF, Zazueta C, et al. Mitochondria as a target in the therapeutic properties of curcumin. Arch Pharm. 2014;347:873–884.
   PubMed Web of Science ®Google Scholar
• Belkacemi A, Doggui S, Dao L, et al. Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med. 2011;13:e34.
   PubMed Web of Science ®Google Scholar
• Cole GM, Frautschy SA. Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer’s disease mouse model. Nutr Health. 2006;18:249–259.
   PubMedGoogle Scholar
• Kumar A, Sehgal N, Kumar P, et al. Protective effect of quercetin against ICV colchicine-induced cognitive dysfunctions and oxidative damage in rats. Phytother Res. 2008;22:1563–1569.
   PubMed Web of Science ®Google Scholar
• de Boer VC, Dihal AA, van der Woude H, et al. Tissue distribution of quercetin in rats and pigs. J Nutr. 2005;135:1718–1725.
   PubMed Web of Science ®Google Scholar
• Shen C, Chen L, Jiang L, et al. Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma. Neurosci Lett. 2015;600:132–136.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang J, Derreumaux P, et al. Molecular mechanism of the inhibition of EGCG on the Alzheimer Abeta(1-42) dimer. J Phys Chem. 2013;117:3993–4002.
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE, Duennwald M, Markovic P, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington’s disease models. Hum Mol Genet. 2006;15:2743–2751.
   PubMed Web of Science ®Google Scholar
• Kang KS, Wen Y, Yamabe N, et al. Dual beneficial effects of (-)-epigallocatechin-3 gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies. PLoS One. 2010;5:11951.
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506.
   PubMed Web of Science ®Google Scholar
• Sun J, Yz L, Yh D, et al. Neuroprotective effects of gallic acid against hypoxia/reoxygenation-induced mitochondrial dysfunctions in vitro and cerebral ischemia/reperfusion injury in vivo. Brain Res. 2014;1589:126–139.
   PubMed Web of Science ®Google Scholar
• Misra S, Tiwari V, Kuhad A, et al. Modulation of nitrergic pathway by sesamol prevents cognitive deficits and associated biochemical alterations in intracerebroventricular streptozotocin administered rats. Eur J Pharmacol. 2011;659:177–186.
   PubMed Web of Science ®Google Scholar
• Szeto HH. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antioxid Redox Signal. 2008;10:601–619.
   PubMed Web of Science ®Google Scholar
• Smith RA, Porteous CM, Coulter CV, et al. Selective targeting of an antioxidant to mitochondria. Eur J Biochem. 1999;263:709–716.
   PubMedGoogle Scholar
• Trnka J, Blaikie FH, Smith RA, et al. A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria. Free Radic Biol Med. 2008;44:1406–1419.
   PubMed Web of Science ®Google Scholar
• Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res. 2006;23:1417–1450.
   PubMed Web of Science ®Google Scholar
• Lu JM, Wang X, Marin-Muller C, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9:325–341.
   PubMed Web of Science ®Google Scholar
• Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J. Biomater Sci Polym. 2006;17:247–289.
   PubMed Web of Science ®Google Scholar
• Swarnakar NK, Jain AK, Singh RP, et al. Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles. Biomaterials. 2011;32:6860–6874.
   PubMed Web of Science ®Google Scholar
• Martins S, Sarmento B, Ferreira DC, et al. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int J Nanomedicine. 2007;2:595–607.
   PubMed Web of Science ®Google Scholar
• Cui J, Yu B, Zhao Y, et al. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm. 2009;371:148–155.
   PubMed Web of Science ®Google Scholar
• Tran TH, Guo Y, Song D, et al. Quercetin-containing self-nanoemulsifying drug delivery system for improving oral bioavailability. J Pharm Sci. 2014;103:840–852.
   PubMed Web of Science ®Google Scholar
• Ali MH, Moghaddam B, Kirby DJ, et al. The role of lipid geometry in designing liposomes for the solubilisation of poorly water soluble drugs. Int J Pharm. 2013;453:225–232.
   PubMed Web of Science ®Google Scholar
• Teshima M, Kawakami S, Fumoto S, et al. PEGylated liposomes loading palmitoyl prednisolone for prolonged blood concentration of prednisolone. Biol Pharm Bull. 2006;29:1436–1440.
   PubMed Web of Science ®Google Scholar
• Biswas S, Dodwadkar NS, Piroyan A, et al. Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondria. Biomaterials. 2012;33:4773–4782.
   PubMed Web of Science ®Google Scholar
• Xiang SD, Wilson K, Day S, et al. Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers. Methods. 2013;60:232–241.
   PubMed Web of Science ®Google Scholar
• Grillone A, Riva ER, Mondini A, et al. Active targeting of sorafenib: preparation, characterization, and in vitro testing of drug-loaded magnetic solid lipid nanoparticles. Adv Healthc Mater. 2015;4:1681–1690.
   PubMed Web of Science ®Google Scholar
• Weissig V, Torchilin VP. Towards mitochondrial gene therapy: DQAsomes as a strategy. J Drug Target. 2001;9:1–13.
   PubMed Web of Science ®Google Scholar
• D’Souza GG, Boddapati SV, Weissig V. Mitochondrial leader sequence-plasmid DNA conjugates delivered into mammalian cells by DQAsomes co-localize with mitochondria. Mitochondrion. 2005;5:352–358.
   PubMed Web of Science ®Google Scholar
• Kumar P, Kalonia H, Kumar A. Sesamol attenuate 3-nitropropionic acid-induced Huntington-like behavioral, biochemical, and cellular alterations in rats. J Asian Nat Prod Res. 2009;11:439–450.
   PubMed Web of Science ®Google Scholar
• Hao S, Ji J, Zhao H, et al. Mitochondrion-targeted peptide SS-31 inhibited oxidized low-density lipoproteins-induced foam cell formation through both ROS scavenging and inhibition of cholesterol influx in RAW264.7 cells. Molecules. 2015;20:21287–21297.
   PubMed Web of Science ®Google Scholar
• Reznickova A, Novotna Z, Kvitek O, et al. Gold, silver and carbon nanoparticles grafted on activated polymers for biomedical applications. J Nanosci Nanotechnol. 2015;15:10053–10073.
   PubMed Web of Science ®Google Scholar
• de Mello Donegá C. Synthesis and properties of colloidal heteronanocrystals. Chem Soc Rev. 2011;40:1512–1546.
   PubMed Web of Science ®Google Scholar
• Fanizza E, Iacobazzi RM, Laquintana V, et al. Highly selective luminescent nanostructures for mitochondrial imaging and targeting. Nanoscale. 2016;8:3350–3361.
   PubMed Web of Science ®Google Scholar
• Battigelli A, Russier J, Venturelli E, et al. Peptide-based carbon nanotubes for mitochondrial targeting. Nanoscale. 2013;5:9110–9117.
   PubMed Web of Science ®Google Scholar
• Yoong SL, Wong BS, Zhou QL, et al. Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin. Biomaterials. 2014;35:748–759.
   PubMed Web of Science ®Google Scholar
• Niu J, Wang K, Kolattukudy PE. Cerium oxide nanoparticles inhibit oxidative stress and nuclear factor-κB activation in H9c2 cardiomyocytes exposed to cigarette smoke extract. J Pharmacol Exp Ther. 2011;338:53–61.
   PubMed Web of Science ®Google Scholar
• Schubert D, Dargusch R, Raitano J, et al. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem Biophys Res Commun. 2006;342:86–91.
   PubMed Web of Science ®Google Scholar
• Ciofani G, Genchi GG, Mazzolai B, et al. Transcriptional profile of genes involved in oxidative stress and antioxidant defense in PC12 cells following treatment with cerium oxide nanoparticles. Biochim Biophys Acta. 2014;1840:495–506.
   PubMed Web of Science ®Google Scholar